Oramed Pharmaceuticals 관리

관리 기준 확인 3/4

Oramed Pharmaceuticals CEO는 Nadav Kidron, Mar2006 에 임명되었습니다 의 임기는 18.67 년입니다. 총 연간 보상은 $ 1.66M, 27.9% 로 구성됩니다. 27.9% 급여 및 72.1% 보너스(회사 주식 및 옵션 포함). 는 € 2.86M 가치에 해당하는 회사 주식의 3.18% 직접 소유합니다. 2.86M. 경영진과 이사회의 평균 재임 기간은 각각 11.9 년과 8.2 년입니다.

주요 정보

Nadav Kidron

최고 경영자

US$1.7m

총 보상

CEO 급여 비율	27.9%
CEO 임기	18.7yrs
CEO 소유권	3.2%
경영진 평균 재임 기간	11.9yrs
이사회 평균 재임 기간	8.2yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Nadav Kidron 의 보수는 Oramed Pharmaceuticals 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	US$4m
Jun 30 2024	n/a	n/a	US$21m
Mar 31 2024	n/a	n/a	US$10m
Dec 31 2023	US$2m	US$463k	US$6m
Sep 30 2023	n/a	n/a	-US$16m
Jun 30 2023	n/a	n/a	-US$20m
Mar 31 2023	n/a	n/a	-US$30m
Dec 31 2022	US$7m	US$491k	-US$37m
Sep 30 2022	n/a	n/a	-US$46m
Jun 30 2022	n/a	n/a	-US$46m
Mar 31 2022	n/a	n/a	-US$40m
Dec 31 2021	n/a	n/a	-US$35m
Nov 30 2021	n/a	n/a	-US$25m
Aug 31 2021	US$4m	US$466k	-US$22m
May 31 2021	n/a	n/a	-US$18m
Feb 28 2021	n/a	n/a	-US$15m
Dec 31 2020	n/a	n/a	-US$22m
Nov 30 2020	n/a	n/a	-US$15m
Aug 31 2020	US$2m	US$439k	-US$12m
May 31 2020	n/a	n/a	-US$11m
Feb 29 2020	n/a	n/a	-US$13m
Nov 30 2019	n/a	n/a	-US$13m
Aug 31 2019	US$2m	US$419k	-US$14m
May 31 2019	n/a	n/a	-US$15m
Feb 28 2019	n/a	n/a	-US$15m
Nov 30 2018	n/a	n/a	-US$14m
Aug 31 2018	US$2m	US$436k	-US$13m

보상 대 시장: Nadav 의 총 보상 ($USD 1.66M )은 German 시장( $USD 472.15K ).

보상과 수익: Nadav 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Nadav Kidron (50 yo)

18.7yrs

테뉴어

US$1,659,222

보상

Mr. Nadav Kidron, Esq. has been the Chief Executive Officer and President of Oramed Pharmaceuticals Inc. (Alternatively Integrated Security Technologies Inc) since March 08, 2006. Mr. Kidron served as an i...

리더십 팀

이름	위치	테뉴어	보상	소유권
Nadav Kidron	President	18.7yrs	US$1.66m	3.18% € 2.9m
Miriam Kidron	Chief Scientific Officer & Director	18.7yrs	US$1.11m	1.07% € 960.7k
Avraham Gabay	CFO, Treasurer & Secretary	less than a year	US$1.05m	0.074% € 66.9k
Joshua Hexter	Chief Operating & Business Officer	5.2yrs	US$1.28m	0.76% € 686.7k

11.9yrs

평균 재임 기간

52yo

평균 연령

경험이 풍부한 관리: OJU1 의 관리팀은 노련하고 경험 (평균 재직 기간 11.9 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Nadav Kidron	President	18.7yrs	US$1.66m	3.18% € 2.9m
Miriam Kidron	Chief Scientific Officer & Director	18.7yrs	US$1.11m	1.07% € 960.7k
Jay Skyler	Member of Scientific Advisory Board	4.8yrs	데이터 없음	데이터 없음
Eleuterio Ferrannini	Member of Scientific Advisory Board	17.8yrs	데이터 없음	데이터 없음
Harold Jacob	Member of Scientific Advisory Board	8yrs	US$20.00k	데이터 없음
Avram Hershko	Member of Scientific Advisory Board	16.3yrs	데이터 없음	데이터 없음
G. Alexander Fleming	Member of Scientific Advisory Board	4.9yrs	데이터 없음	데이터 없음
Leonard Sank	Independent Director	17.1yrs	US$112.28k	0.081% € 72.5k
Roy Eldor	Member of the Scientific Advisory Board	8.3yrs	데이터 없음	데이터 없음
Anne Peters	Member of Scientific Advisory Board	2.4yrs	데이터 없음	데이터 없음
Arie Mayer	Independent Director	4.9yrs	US$127.28k	0.076% € 68.3k
Julio Rosenstock	Member of Scientific Advisory Board	4.8yrs	데이터 없음	데이터 없음

8.2yrs

평균 재임 기간

70yo

평균 연령

경험이 풍부한 이사회: OJU1 의 이사회는 경험(평균 재직 기간 8.2 년)으로 간주됩니다.

Oramed Pharmaceuticals 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Oramed Pharmaceuticals Inc., Annual General Meeting, Aug 01, 2024

Oramed Pharmaceuticals Inc. Appoints Mr. Avraham Gabay as Treasurer and Secretary, Effective as of June 18, 2024

Insufficient new directors

Oramed Pharmaceuticals Inc. Appoints Daniel Aghion as Director, Effective January 1, 2024

Oramed Pharmaceuticals Inc., Annual General Meeting, Jul 13, 2023

Oramed Pharmaceuticals Inc., Annual General Meeting, Jul 13, 2023

Recent updates

New major risk - Earnings quality

Investor sentiment deteriorates as stock falls 15%

New minor risk - Market cap size

Investor sentiment improves as stock rises 22%

Oramed Pharmaceuticals Inc. (NasdaqCM:ORMP) announces an Equity Buyback for $20 million worth of its shares.

Oramed Pharmaceuticals Inc. (NasdaqCM:ORMP) announces an Equity Buyback for $20 million worth of its shares.

Oramed Pharmaceuticals Inc., Annual General Meeting, Aug 01, 2024

Oramed Pharmaceuticals Inc. Appoints Mr. Avraham Gabay as Treasurer and Secretary, Effective as of June 18, 2024

Investor sentiment improves as stock rises 17%

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: EPS: US$0.038 (vs US$0.085 loss in 1Q 2023)

New minor risk - Market cap size

Oramed Pharmaceuticals Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Full year 2023 earnings released: EPS: US$0.14 (vs US$0.94 loss in FY 2022)

Insufficient new directors

Oramed Pharmaceuticals Inc. Appoints Daniel Aghion as Director, Effective January 1, 2024

Third quarter 2023 earnings released: US$0.08 loss per share (vs US$0.18 loss in 3Q 2022)

New major risk - Share price stability

New minor risk - Market cap size

Second quarter 2023 earnings released: US$0.03 loss per share (vs US$0.27 loss in 2Q 2022)

Oramed Pharmaceuticals Inc. (NasdaqCM:ORMP) entered into a Stalking Horse Stock Purchase Term Sheet to acquire a 40.17% stake in Scilex Holding Company (NasdaqCM:SCLX) from Sorrento Therapeutics, Inc. (OTCPK:SRNE.Q) for approximately $110 million.

Oramed Pharmaceuticals Inc., Annual General Meeting, Jul 13, 2023

Oramed Pharmaceuticals Inc., Annual General Meeting, Jul 13, 2023

First quarter 2023 earnings released: US$0.085 loss per share (vs US$0.27 loss in 1Q 2022)

President recently bought €188k worth of stock

Independent Director recently bought €132k worth of stock

Full year 2022 earnings released: US$0.94 loss per share (vs US$0.94 loss in FY 2021)

Oramed Pharmaceuticals Inc. Announces Top-Line Results from Phase 3 Trial of ORMD-0801 for the Treatment of Type 2 Diabetes

Oramed Pharmaceuticals Inc. Granted U.S. Combination Therapy Patent for Oral Glp-1 & Insulin for the Treatment of Diabetes

Oramed Announces Additional Positive Safety and Efficacy Data from Its Phase 2 Clinical Trial of ORMD-0801 for NASH

Third quarter 2022 earnings released: US$0.18 loss per share (vs US$0.21 loss in 3Q 2021)

High number of new and inexperienced directors

Third quarter 2022 earnings released: US$0.18 loss per share (vs US$0.21 loss in 3Q 2021)

Oramed Pharmaceuticals Inc. Reports Positive Top-Line Results from Phase 2 Nash Trial with its ORMD-0801, Oral Insulin Candidate

Second quarter 2022 earnings released: US$0.27 loss per share (vs US$0.17 loss in 2Q 2021)

Oramed Reaches 50% Enrollment in Its Second Phase 3 Oral Insulin Trial

High number of new and inexperienced directors

Oramed Pharmaceuticals Inc., Annual General Meeting, Jun 30, 2022

Oramed Pharmaceuticals Inc. Appoints Anne Peters to Its Scientific Advisory Board

First quarter 2022 earnings released: US$0.27 loss per share (vs US$0.17 loss in 1Q 2021)

Oramed Pharmaceuticals Inc. Completes Patient Enrollment in Pivotal Phase 3 Oral Insulin Study Ora-D-013-1

Oramed Pharmaceuticals Inc. Grants NASH Patent in Europe

Full year 2021 earnings released: US$0.94 loss per share (vs US$0.90 loss in FY 2020)

Independent Chairman of the Board recently sold €85k worth of stock

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Oramed Subsidiary Oravax Announces First Participant Enrolled in Phase 1 Oral Covid-19 Vaccine Trial in South Africa

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Oramed Pharmaceuticals Inc. Reaches 75% Enrollment in Phase 3 Oral Insulin Study

Independent Chairman of the Board recently sold €376k worth of stock

Independent Director Xiaoming Gao has left the company

Oramed Pharmaceuticals Inc. Reaches 25% Enrollment in Its Second of Two Concurrent Phase 3 Oral Insulin Trials

Oramed Pharmaceuticals Inc. Provides Update on Oravax: Oral Vaccine Maker Gets IRB Approval for Clinical Trial

Third quarter 2021 earnings released: US$0.17 loss per share (vs US$0.098 loss in 3Q 2020)

CFO, Treasurer & Secretary Avraham Gabay has left the company

Oramed Reaches 50% Enrollment in Phase 3 Oral Insulin Study

Second quarter 2021 earnings released: US$0.17 loss per share (vs US$0.21 loss in 2Q 2020)

Oramed Pharmaceuticals Inc. Reaches 25% Randomization in World's First Phase 3 Oral Insulin Study Conducted Under FDA Approved Protocol

New 90-day high: €9.23

New 90-day high: €5.31

Oramed Pharmaceuticals Inc. Doses Patients Across Multiple Sites in Phase 3 Oral Insulin Study

Revenue beats expectations

Revenue beats expectations

First quarter 2021 earnings released: US$0.23 loss per share

Oramed Pharmaceuticals Inc. Reports Positive First in Human Data from Oral Leptin Study

Oramed Pharmaceuticals Inc. Initiates Phase 2 NASH Trial of Oral Insulin

New 90-day high: €3.34

Revenue misses expectations

Oramed Pharmaceuticals Inc Initiates Phase 3 Trial of Oral Insulin

Full year 2020 earnings released: US$0.56 loss per share